PD12-01 DOES CO-MEDICATION WITH NON-ANTICANCER DRUGS AFFECT OUTCOMES IN PATIENTS WITH SURGICALLY TREATED CLEAR CELL RENAL CELL CARCINOMA ? - EVALUATION OF SURVIVAL, CELL-CYCLE ACTIVITY, AND PROLIFERATION
2018-04-01

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy II1 Apr 2018PD12-01 DOES CO-MEDICATION WITH NON-ANTICANCER DRUGS AFFECT OUTCOMES IN PATIENTS WITH SURGICALLY TREATED CLEAR CELL RENAL CELL CARCINOMA ? - EVALUATION OF SURVIVAL, CELL-CYCLE ACTIVITY, AND PROLIFERATION Steffen Rausch, Eva Neumann, Peter Klaiber, Kathleen Freitag, Matthias Schwab, Elke Schaeffeler, Jörg Hennenlotter, Falko Fend, Stephan Kruck, Marcus Scharpf, Arnulf Stenzl, and Jens Bedke Steffen RauschSteffen Rausch More articles by this author , Eva NeumannEva Neumann More articles by this author , Peter KlaiberPeter Klaiber More articles by this author , Kathleen FreitagKathleen Freitag More articles by this author , Matthias SchwabMatthias Schwab More articles by this author , Elke SchaeffelerElke Schaeffeler More articles by this author , Jörg HennenlotterJörg Hennenlotter More articles by this author , Falko FendFalko Fend More articles by this author , Stephan KruckStephan Kruck More articles by this author , Marcus ScharpfMarcus Scharpf More articles by this author , Arnulf StenzlArnulf Stenzl More articles by this author , and Jens BedkeJens Bedke More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.637AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Several non-anticancer drugs have been discussed as effective in renal cell carcinoma (RCC). We investigated the impact of concomitant medication with non-anticancer drugs at time of surgery on overall survival (OS) in an institutional clear cell RCC (ccRCC) cohort. Furthermore, we correlated co-medication with cell-cycle and proliferation activity in corresponding surgical specimen. METHODS A total of 388 patients who underwent surgery for localized clear cell renal cell carcinoma at our institution from 1993 to 2011 were included. Clinical and pathological standard variables and follow-up were recorded. The individual medication of patients at the time of surgery was evaluated according to substance classes. Tissue microarrays (TMA) from corresponding tumor specimen were immunohistochemically (IHC) stained for Cyclin D1 and Ki67 and semi-quantitatively evaluated. Kaplan-Meier analysis and uni- and multivariate Cox proportional hazards regression analysis were used to compare survival outcomes. For the comparison of IHC expression according to medication subgroups, Kruskal-Wallis analysis was performed. RESULTS Clinical follow-up was available in 373 (96.1%) of the ccRCC patients with a median follow-up of 57.93 months (95% CI 53.27-69.43) and median OS of 181.12 months (95% CI 129.72-237.17). A total of 140 (37.5%) patients died during follow-up. A complete history of medication was available in 246 (63.4%) patients. Univariate analysis identified pathological standard variables (T-stage >T2, Grading >G2, L1, N1, M1, sarcomatiod subtype, necrosis) as significant determinants of OS (all p<0.001). Among the investigated medication, statin use (p= 0.009) and sartan use (p= 0.032) were significantly associated with improved OS. Multivariate Cox regression analysis identified M1-stage (p <0.001), statin and sartan use (p= 0.003 and p= 0.033, respectively) as independent prognosticators of OS in patients with ccRCC. Expression of Ki67 was significantly reduced in patients with statin use (p=0.013) while Cyclin D1 expression showed no correlation in dependence of co-medication. CONCLUSIONS Concomitant intake of statins and sartans was an independent predictor of OS in surgically treated primary ccRCC, and reduced Ki67 expression was significantly associated with statin use. Therefore, further evaluation of drug repurposing approaches with these substances in RCC are warranted. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e239 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Steffen Rausch More articles by this author Eva Neumann More articles by this author Peter Klaiber More articles by this author Kathleen Freitag More articles by this author Matthias Schwab More articles by this author Elke Schaeffeler More articles by this author Jörg Hennenlotter More articles by this author Falko Fend More articles by this author Stephan Kruck More articles by this author Marcus Scharpf More articles by this author Arnulf Stenzl More articles by this author Jens Bedke More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...